Efficacia e tollerabilita a lungo termine del vigabatrin come terapia aggiuntiva nelle epilessie farmacoresistenti dell'adulto

A. Tartara; R. Manni; C. Galimberti; I. Sartori; R. Murelli; E. Marchioni; E. Perucca

Efficacia e tollerabilita a lungo termine del vigabatrin come terapia aggiuntiva nelle epilessie farmacoresistenti dell'adulto

Translated title of the contribution: Long term efficacy and tolerability of Vigabatrin as add-on treatment in adult refractory epilepsy

A. Tartara, R. Manni, C. Galimberti, I. Sartori, R. Murelli, E. Marchioni, E. Perucca

Fondazione "Istituto Neurologico Casimiro Mondino"

Research output: Contribution to journal › Article › peer-review

Abstract

After a mean follow-up of 34 months (range 6-161 months) 52% of 162 patients with refractory epilepsy (mostly with partial seizures) continue on add-on Vigabatrin treatment. Ten percent are seizure-free and an additional 12% achieved a greater than 75% reduction in seizures frequency. None of the patients with generalized epilepsies responded. Only 11% discontinued treatment because of adverse effects, usually within the first 6 months.

Translated title of the contribution	Long term efficacy and tolerability of Vigabatrin as add-on treatment in adult refractory epilepsy
Original language	Italian
Pages (from-to)	23-25
Number of pages	3
Journal	Bollettino - Lega Italiana contro l'Epilessia
Issue number	99 SUPPL. 1
Publication status	Published - 1997

ASJC Scopus subject areas

Clinical Neurology

Fingerprint Dive into the research topics of 'Long term efficacy and tolerability of Vigabatrin as add-on treatment in adult refractory epilepsy'. Together they form a unique fingerprint.

Cite this

Efficacia e tollerabilita a lungo termine del vigabatrin come terapia aggiuntiva nelle epilessie farmacoresistenti dell'adulto. / Tartara, A.; Manni, R.; Galimberti, C.; Sartori, I.; Murelli, R.; Marchioni, E.; Perucca, E.

In: Bollettino - Lega Italiana contro l'Epilessia, No. 99 SUPPL. 1, 1997, p. 23-25.

Research output: Contribution to journal › Article › peer-review

@article{4dc5027baa294f20ac755e0b0f38227d,

title = "Efficacia e tollerabilita a lungo termine del vigabatrin come terapia aggiuntiva nelle epilessie farmacoresistenti dell'adulto",

abstract = "After a mean follow-up of 34 months (range 6-161 months) 52% of 162 patients with refractory epilepsy (mostly with partial seizures) continue on add-on Vigabatrin treatment. Ten percent are seizure-free and an additional 12% achieved a greater than 75% reduction in seizures frequency. None of the patients with generalized epilepsies responded. Only 11% discontinued treatment because of adverse effects, usually within the first 6 months.",

keywords = "Drug-refractory Epilepsy, Tolerance, Vigabatrin",

author = "A. Tartara and R. Manni and C. Galimberti and I. Sartori and R. Murelli and E. Marchioni and E. Perucca",

year = "1997",

language = "Italian",

pages = "23--25",

journal = "Bollettino - Lega Italiana contro l'Epilessia",

issn = "0394-560X",

publisher = "Lega Italiana contro l'Epilessia",

number = "99 SUPPL. 1",

}

TY - JOUR

T1 - Efficacia e tollerabilita a lungo termine del vigabatrin come terapia aggiuntiva nelle epilessie farmacoresistenti dell'adulto

AU - Tartara, A.

AU - Manni, R.

AU - Galimberti, C.

AU - Sartori, I.

AU - Murelli, R.

AU - Marchioni, E.

AU - Perucca, E.

PY - 1997

Y1 - 1997

N2 - After a mean follow-up of 34 months (range 6-161 months) 52% of 162 patients with refractory epilepsy (mostly with partial seizures) continue on add-on Vigabatrin treatment. Ten percent are seizure-free and an additional 12% achieved a greater than 75% reduction in seizures frequency. None of the patients with generalized epilepsies responded. Only 11% discontinued treatment because of adverse effects, usually within the first 6 months.

AB - After a mean follow-up of 34 months (range 6-161 months) 52% of 162 patients with refractory epilepsy (mostly with partial seizures) continue on add-on Vigabatrin treatment. Ten percent are seizure-free and an additional 12% achieved a greater than 75% reduction in seizures frequency. None of the patients with generalized epilepsies responded. Only 11% discontinued treatment because of adverse effects, usually within the first 6 months.

KW - Drug-refractory Epilepsy

KW - Tolerance

KW - Vigabatrin

UR - http://www.scopus.com/inward/record.url?scp=0030694408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030694408&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0030694408

SP - 23

EP - 25

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 99 SUPPL. 1

ER -